The Breakthrough Therapy designation was granted based on interim results of a phase I trial, which the companies developing the agent have not yet released. (cancernetwork.com)
ACT is expecting to report more interim results of its Phase 1/2 trial later this year. (stemcellassays.com)
The company is expecting to present interim results of Phase 2 (expanded to 21 centers) at the end of the year. (stemcellassays.com)